Immunotherapeutic strategies in kidney cancer--when TKIs are not enough (Q37527800)

20 August 2017

1 reference

title

Immunotherapeutic strategies in kidney cancer--when TKIs are not enough (English)

1 reference

20 August 2017

1 reference

Swethajit Biswas

1

1 reference

PubMed ID

19546865

20 August 2017

Tim Eisen

series ordinal

2

1 reference

PubMed ID

19546865

20 August 2017

language of work or name

English

0 references

publication date

23 June 2009

1 reference

Nature Reviews Clinical Oncology

20 August 2017

1 reference

20 August 2017

6

1 reference

20 August 2017

8

1 reference

20 August 2017

478-487

1 reference

Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma

20 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Renal cell carcinoma: etiology, incidence and epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Immunologic dysfunction in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

The effect of CpG-ODN on antigen presenting cells of the foal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Regulatory T cells and toll-like receptors in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Cancer's molecular sweet tooth and the Warburg effect.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Inhibitory effect of tumor cell-derived lactic acid on human T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

A2A adenosine receptor protects tumors from antitumor T cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Adenosine receptors in regulation of dendritic cell differentiation and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

EDB fibronectin and angiogenesis -- a novel mechanistic pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Vascular endothelial growth factor (VEGF) and ovarian carcinoma cell supernatant activate signal transducers and activators of transcription (STATs) via VEGF receptor-2 (KDR) in human hemopoietic progenitor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Macrophages regulate the angiogenic switch in a mouse model of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Autocrine Production of IL-10 Mediates Defective IL-12 Production and NF- B Activation in Tumor-Associated Macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Tumor escape mechanism governed by myeloid-derived suppressor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Bv8 regulates myeloid-cell-dependent tumour angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

A cytokine-mediated link between innate immunity, inflammation, and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Interleukin 2 for patients with renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Impact of immune parameters on long-term survival in metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Cytokine therapy: a standard of care for metastatic renal cell carcinoma?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Update on the application of interleukin-2 in the treatment of renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

New insights into form and function of fibronectin splice variants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Adoptive T cell therapy for cancer in the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.91

Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.

31 March 2020

1 reference

12 December 2020

The natural history of metastatic renal cell carcinoma: a computer analysis

1 reference

12 December 2020

The Role of Adjunctive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma

1 reference

12 December 2020

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy

1 reference

12 December 2020

Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells

1 reference

12 December 2020

Extracellular matrix and cardiac remodelling.

1 reference

12 December 2020

Immunotherapy for advanced renal cell cancer

1 reference

12 December 2020

CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion.

1 reference

12 December 2020

10.1038/NRCLINONC.2009.91

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19546865